Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Read why GNFT stock's ...
manilatimes9 天
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with ...
No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...